Camber Capital Management LP Glycomimetics Inc Transaction History

Camber Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $6.36 Million - $9.28 Million	-2,200,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.69 - $4.24 $807,000 - $1.27 Million	-300,000 Reduced 12.0%	2,200,000 $8.27 Million
Q3 2020 Nov 16, 2020	SELL	$3.07 - $5.0 $1.54 Million - $2.5 Million	-500,000 Reduced 16.67%	2,500,000 $7.68 Million
Q2 2020 Aug 14, 2020	SELL	$2.06 - $3.76 $1.03 Million - $1.88 Million	-500,000 Reduced 14.29%	3,000,000 $11.3 Million
Q3 2019 Nov 14, 2019	BUY	$2.8 - $12.85 $9.8 Million - $45 Million	3,500,000 New	3,500,000 $15.1 Million

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.